DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for glottis carcinoma — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGlottis carcinoma maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for glottis carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p53 (TP53) — TP53 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9R2Q · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
A 20-year retrospective study of 141 patients treated with definitive radiotherapy for T1-T2 glottic squamous cell carcinoma reported five-year local control of 94% for T1a, 83% for T1b, 87% for T2a, and 65% for T2b. Ten-year local control fell to 89% for T1a, 83% for T1b, 87% for T2a, and 53% for T2b. The cumulative incidence of death due to larynx cancer at ten years was 5.5%. Five-year cause-specific survival was 95.9% and overall survival 76.8%. Chronic laryngeal edema occurred in 18% and dysphagia in 7%. On multivariate analysis, T-stage, heavy alcohol consumption during treatment, and use of weighted fields predicted poor outcome. The authors concluded that alternative management should be pursued for T2b tumours.
A cross-sectional study of 43 patients with stage II (T2N0M0) glottic carcinoma reported 100% overall survival and disease-specific survival, with 11.62% locoregional recurrence over 24 months of follow-up. Voice preservation was 86.04%. Radiotherapy was used in 72.09% of patients, chemoradiation in 18.60%, and surgery in 11.62%. 2.32% of patients required tracheostomy. The study did not report separate outcomes by treatment modality, so no comparison between radiotherapy, chemoradiation, and surgery is possible from these data. The authors advocated proactive prevention rather than treatment escalation.
A single case report described a patient with T1a glottic carcinoma in whom staging imaging could not differentiate a jugular vein aneurysm from a metastatic node; the aneurysm was identified only during surgery.
What remains missing is prospective data comparing radiotherapy, chemoradiation, and surgery head-to-head for T2 disease, particularly for the T2b subgroup where radiotherapy outcomes are worse. No trial has yet stratified patients by paraglottic space invasion or smoking status to guide treatment selection. The 2012 study is retrospective and spans 20 years, during which techniques changed. The 2021 study is small, single-centre, and short follow-up. No randomised evidence exists for adding chemotherapy to radiotherapy in early glottic carcinoma.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Radiation Oncology · 2012 · 75 citations · open access
Definitive radiotherapy for early (T1-T2) Glottic Squamous cell carcinoma: a 20 year Cleveland clinic experience
AbstractPURPOSE: To report our 20 yr experience of definitive radiotherapy for early glottic squamous cell carcinoma (SCC). METHODS AND MATERIALS: Radiation records of 141 patients were retrospectively evaluated for patient, tumor, and treatment characteristics. Cox proportional hazard models were used to perform univariate (UVA) and multivariate analyses (MVA). Cause specific survival (CSS) and overall survival (OS) were plotted using cumulative incidence and Kaplan-Meir curves, respectively. RESULTS: Of the 91% patients that presented with impaired voice, 73% noted significant improvement. Chronic laryngeal edema and dysphagia were noted in 18% and 7%, respectively. The five year LC was 94% (T1a), 83% (T1b), 87% (T2a), 65% (T2b); the ten year LC was 89% (T1a), 83% (T1b), 87% (T2a), and 53% (T2b). The cumulative incidence of death due to larynx cancer at 10 yrs was 5.5%, respectively. On MVA, T-stage, heavy alcohol consumption during treatment, and used of weighted fields were predictive for poor outcome (p < 0.05). The five year CSS and OS was 95.9% and 76.8%, respectively. CONCLUSIONS: Definitive radiotherapy provides excellent LC and CSS for early glottis carcinoma, with excellent voice preservation and minimal long term toxicity. Alternative management strategies should be pursued for T2b glottis carcinomas.
Journal of Evidence Based Medicine and Healthcare · 2021 · 0 citations · open access
A Cross Sectional Study on Loco-Regional Recurrences and Overall Survival Rate among Patients with Stage II (T2N0M0) Glottis Carcinoma Treated with Chemoradiation and Surgery
AbstractBACKGROUND Single modality treatment for stage I and stage II squamous cell carcinomas of glottis region gave excellent results. Since a long time these are treated either with definitive radiation therapy or surgical excision with endoscopes. There was not much difference with regard to voice preservation, local recurrence and disease-free survival period. Our aim was to study the clinical presentation and management protocol of glottis carcinoma in a tertiary hospital and observe the final outcome of stage II (T2N0M0) glottis carcinoma and specific factor for survival in patients treated with surgery, radiotherapy and concurrent chemoradiation. METHODS 43 patients of glottis carcinoma stage II (T2N0M0) attending a tertiary teaching hospital between May 2015 and April 2017 were included in the study. Demography and smoking status of subjects were recorded. Staging of the disease was according to American Joint Committee on Cancer (AJCC) Staging System 7th edition. Paraglottic space infiltration was taken as a criteria to upgrade the staging. The overall survival rate, recurrence free survival, disease specific survival rate and laryngeal function preservation rate were calculated. RESULTS Out of 43 patients, males were 90.69 % and 09.30 % were females. Male to female ratio was 10.57 : 1. Mean age was 58.62 ± 2.35 years. 67.44 % were current smokers, 27.90 % were former smokers and 02.32 % were non-smokers. The overall survival scores and disease specific survival was 100 % with 11.62 % locoregional recurrences. The voice preservation was 86.04 %. Radiotherapy was used in 72.09 %, chemoradiation in 18.60 % patients and 11.62 % patients underwent surgery. 11.62 % patients presented with locoregional recurrence during 24 months of follow up. 02.32 % patients had to undergo tracheostomy. CONCLUSIONS The overall survival scores and disease specific survival were 100 % with 11.62 % loco-regional recurrence. Voice preservation was 86.04 %. Proactive prevention rather than escalation of treatment protocol gives better prognosis. KEYWORDS Glottis, Larynx, Supra Glottis, Sub Glottis, Squamous Cell Carcinoma, Chemo Radiation and Trans Oral Laryngeal Surgeries
Laryngo-Rhino-Otologie · 2019 · 0 citations · open access
Unusual incidental finding in the staging of a T1a-glottic carcinoma
AbstractThe recognition of cervical masses of the neck is through the combination of several imaging procedures already preoperatively very well possible. Rarely the entity of the lesion is only during surgery certainly differentiable. The following case report shows a rare additional finding, that was during staging of a glottis carcinoma not structurally differentiable. It was only identified as jugular vein aneurysm during surgery.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
